Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

Trial Profile

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lifileucel (Primary) ; LN 145 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Ipilimumab; Nivolumab; Pembrolizumab
  • Indications Adenocarcinoma; Head and neck cancer; Large cell carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Iovance Biotherapeutics
  • Most Recent Events

    • 12 Sep 2023 Results (As of 21 Mar 2023) assessing efficacy and safety data for LN-145 autologous TIL cell therapy in combination with pembrolizumab in patients with ICI naive metastatic NSCLC presented at the 24th World Conference on Lung Cancer
    • 25 Jul 2023 According to an Iovance Biotherapeutics media release, cohort 3A data of LN-145 in Combination with Pembrolizumab in Anti-PD1-naive Advanced (metastatic or unresectable) Non-Small Cell Lung Cancer (NSCLC) will be presented as an oral presentation at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.
    • 23 Jan 2023 According to an Iovance Biotherapeutics media release, the company plans to meet with FDA in 2023 to discuss Cohort 3A results and a potential registration trial of lifileucel in frontline advanced NSCLC patients who are EGFR wild-type.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top